| Authors: |
Nir-Paz R; ESGNTA - ESCMID Study Group for Non-Traditional Antibacterials, Basel, Switzerland; Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; Israeli Phage Therapy Center of Hadassah Medical Center and the Hebrew University, Jerusalem, Israel. Electronic address: NIRPAZ@hadassah.org.il., Pirnay JP; ESGNTA - ESCMID Study Group for Non-Traditional Antibacterials, Basel, Switzerland; Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, Brussels, Belgium., Ferry T; ESGNTA - ESCMID Study Group for Non-Traditional Antibacterials, Basel, Switzerland; Infectious Diseases, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Centre interrégional de référence pour la prise en charge des infections ostéoarticulaires complexes, CRIOAc Lyon, Hospices Civils de Lyon, Lyon, France; Claude Bernard Lyon 1 University, Lyon, France., Drulis-Kawa Z; ESGNTA - ESCMID Study Group for Non-Traditional Antibacterials, Basel, Switzerland; Department of Pathogen Biology and Immunology, University of Wroclaw, Wroclaw, Poland., Classen AY; ESGNTA - ESCMID Study Group for Non-Traditional Antibacterials, Basel, Switzerland; Department I for Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Scobie AI; ESGNTA - ESCMID Study Group for Non-Traditional Antibacterials, Basel, Switzerland; Department of Infection, Royal Free London NHS Foundation Trust, UK; Bone Infection Unit, Royal National Orthopaedic Hospital NHS Trust, UK; Division of Infection and Immunity, University College London, UK., Lester R; ESGNTA - ESCMID Study Group for Non-Traditional Antibacterials, Basel, Switzerland; Department of Infection, Royal Free London NHS Foundation Trust, UK; Division of Infection and Immunity, University College London, UK., Katvan E; Law School and Health Management Program, Peres Academic Center, Rehovot, Israel., Hafkemeyer S; Mukoviszidose Institut GmbH, subsidiary of the German Cystic Fibrosis association Mukoviszidose e. V., Bonn, Germany., McCallin S; ESGNTA - ESCMID Study Group for Non-Traditional Antibacterials, Basel, Switzerland; Department of Neuro-Urology, Balgrist University Hospital, University of Zürich, Zürich, Switzerland; Spinal Cord Injury Center, Balgrist University Hospital, University of Zürich, Zürich, CH, Switzerland., Suh GA; ESGNTA - ESCMID Study Group for Non-Traditional Antibacterials, Basel, Switzerland; Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA. |
